News – Page 354 – Endpoints News

The ‘new, old kids’ on the biotech block unveil a $350M stealth science fund. And they’re going very, very ...

3 years ago

Exclusive: Oncology startup from Sanger Institute nabs $28M, ex-Novartis SVP as CEO

3 years ago

Mitochondria biotech field grows as RA, Insight up the Capacity with a new $35M startup

3 years ago

Two patient deaths lead to FDA partial hold for Gossamer trial of lymphoma drug

3 years ago

More than half of accelerated approval confirmatory trials are late, researchers write in JAMA

3 years ago

J&J spinout loses bid to delay talc bankruptcy case as it heads to Supreme Court

3 years ago

Pharma fees to European regulator spike thanks to 10% inflation rate

3 years ago

Ginkgo partners up with Sensible Biotechnologies to forge mRNA manufacturing platform

3 years ago

Survey says drug commercialization should stretch back, incorporate digital insights for doctors

3 years ago

Sandoz to pay Allergan, Duke University $39M over eye drug lawsuit, jury says

3 years ago

FDA reveals cleaning and testing issues at Global Pharma Indian manufacturing site

3 years ago

Pharma faces ripple effects from federal court's cutting of preventive care

3 years ago

Biotech launched during Covid — for Covid — looks for strategic alternatives after antiviral fails PhII trial

3 years ago

Vertex and CRISPR send exa-cel for FDA approval; Aridis Therapeutics axes 20% of its workforce

3 years ago

FDA cites ‘deficiencies’ in Ascendis’ application for parathyroid drug, jeopardizing potential approval

3 years ago

AstraZeneca inks deal with Japanese biotech JCR in CNS indication

3 years ago

Second time’s the charm? Cyclerion CEO tries again at buying biotech's assets

3 years ago

FTC orders Illumina to divest Grail, adding pressure amid activist fight with Icahn

3 years ago

A note to our advertising partners: Endpoints News joins the Financial Times family

3 years ago

Publisher's note

From the founders: Endpoints is now part of the Financial Times family

3 years ago

Publisher's note

BioNTech delves into ADCs with $170M upfront weeks after Pfizer lines up Seagen

3 years ago

Takeda pays $5M upfront to license antibodies for celiac disease drug development

3 years ago

Vedere Bio II, gene therapy biotech born out of Novartis buyout, closes down

3 years ago

Whoops: CMS quietly pares back list of drugs requiring new rebates under Inflation Reduction Act

3 years ago

First page Previous page 351 352 353354355 356 357 Next page Last page